Showing 1,561 - 1,580 results of 1,840 for search '"clinical research"', query time: 0.09s Refine Results
  1. 1561
  2. 1562
  3. 1563
  4. 1564
  5. 1565
  6. 1566
  7. 1567

    Optimizing Obstructive Sleep Apnea Risk Assessment in Hypertension: Development of a Predictive Nomogram in China by Yang Y, Sun X, Liang J, Liao WF, Ye W, Zheng Z, Du L, Chen M, Zhang Y, Lin W, Huang J, Yao W, Chen R

    Published 2025-02-01
    “…Yitian Yang,1,* Xishi Sun,2,* Jinhua Liang,1,* Wei Feng Liao,1,* Weilong Ye,1 Zhenzhen Zheng,1 Lianfang Du,1 Mingdi Chen,1 Yuan Zhang,3 Wenjia Lin,2 Jinyu Huang,2 Weimin Yao,1 Riken Chen1,4 1The Second Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, 524003, People’s Republic of China; 2Emergency Medicine Center, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, 524001, People’s Republic of China; 3The First Clinical School of Medicine, Guangdong Medical University, Zhanjiang, Guangdong, 524003, People’s Republic of China; 4State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, 510120, People’s Republic of China*These authors contributed equally to this workCorrespondence: Riken Chen; Weimin Yao, The Second Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, 524003, People’s Republic of China, Tel +13560244631 ; +13822521722, Email chenriken@126.com; 490296443@qq.comPurpose: Obstructive sleep apnea (OSA) is common in patients with hypertension. …”
    Get full text
    Article
  8. 1568
  9. 1569
  10. 1570
  11. 1571

    PD(L)1 Inhibitors Plus Lenvatinib Vs Atezolizumab Plus Bevacizumab Combined With HAIC for Unresectable HCC: A Propensity Score Matching Study by He Z, Chen H, Liang C, Tang X, Jiang L, Xie F, Liu Q, Zheng Y

    Published 2025-01-01
    “…Zhaoqian He,1– 3,* Hua Chen,1– 3,* Chen Liang,1– 3,* Xiang Tang,1– 3 Lingmin Jiang,1– 3 Feihu Xie,1– 3 Qi Liu,1– 3 Yun Zheng1– 3 1Department of Liver Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, 510060, People’s Republic of China; 2Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, 510060, People’s Republic of China; 3Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, 510060, People’s Republic of China*These authors contributed equally to this workCorrespondence: Yun Zheng; Qi Liu, State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, 510060, People’s Republic of China, Email zhengyun@sysucc.org.cn; liuqi9@sysucc.org.cnPurpose: To compare the clinical outcomes of different systemic therapies, specifically PD(L)1 inhibitors plus Lenvatinib versus Atezolizumab plus Bevacizumab, when combined with hepatic arterial infusion chemotherapy (HAIC) based on the FOLFOX regimen (oxaliplatin, fluorouracil, and leucovorin) as first line treatment for unresectable hepatocellular carcinoma.Patients and Methods: This real-world retrospective study enrolled 294 patients with unresectable HCC. …”
    Get full text
    Article
  12. 1572
  13. 1573
  14. 1574
  15. 1575
  16. 1576
  17. 1577
  18. 1578
  19. 1579
  20. 1580